BMS-754807 (CAS 1001350-96-4)
Alternate Names:
BMS 754807 BMS754807 UNII-W9E3353E8J
CAS Number:
1001350-96-4
Molecular Weight:
461.50
Molecular Formula:
C23H24FN9O
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
BMS-754807 is an inhibitor of IGF-IR.
BMS-754807 (CAS 1001350-96-4) References
- BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. | Carboni, JM., et al. 2009. Mol Cancer Ther. 8: 3341-9. PMID: 19996272
- Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. | Kolb, EA., et al. 2011. Pediatr Blood Cancer. 56: 595-603. PMID: 21298745
- Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. | Hou, X., et al. 2011. Cancer Res. 71: 7597-607. PMID: 22042792
- A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by [(18)F]fluorothymidine-positron emission tomography. | Lee, SJ., et al. 2013. Invest New Drugs. 31: 506-15. PMID: 22987020
- BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer. | Awasthi, N., et al. 2012. Mol Cancer Ther. 11: 2644-53. PMID: 23047891
- IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines. | Huang, F., et al. 2015. Mol Cancer Ther. 14: 620-30. PMID: 25527633
- A high-throughput in vitro drug screen in a genetically engineered mouse model of diffuse intrinsic pontine glioma identifies BMS-754807 as a promising therapeutic agent. | Halvorson, KG., et al. 2015. PLoS One. 10: e0118926. PMID: 25748921
- BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549. | Franks, SE., et al. 2016. BMC Res Notes. 9: 134. PMID: 26928578
- Differential Effects of IGF-1R Small Molecule Tyrosine Kinase Inhibitors BMS-754807 and OSI-906 on Human Cancer Cell Lines. | Fuentes-Baile, M., et al. 2020. Cancers (Basel). 12: PMID: 33322337
- Dasatinib in combination with BMS-754807 induce synergistic cytotoxicity in lung cancer cells through inhibiting lung cancer cell growth, and inducing autophagy as well as cell cycle arrest at the G1 phase. | Zhang, C., et al. 2023. Invest New Drugs. 41: 438-452. PMID: 37097369
Inhibitor of:
A2LD1, ADAMTS-5, BZW1, DEF6, FAM184A, GFAT2, HNF-3γ, IGF-I, IGF-IA, IGF-IB, IGF-II, IGF-IRα, IGF-IRβ, IGF2AS, IGFBP1, IGFBP3, IGFBP4, IGFBP6, IGFBPL1, IGFL2, IGRP, INSL4, INSL5, Insulin II, insulin R, IRS-2, LHX3, LRRK2, PITHD1, and Relaxin 1.Activator of:
GRB7, PRRG1, and Trk C.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BMS-754807, 5 mg | sc-507396 | 5 mg | $304.00 |